MedAdvisor Stock

MedAdvisor ROE

The Return on Equity (ROE) of MedAdvisor (MDR.AX) as of Jun 23, 2026 is -57.41.In the previous year, Return on Equity (ROE) was 0.02 — a change of -373,986.77% (lower).

ROE

-57.41

YoY

-373,986.77%

Last updated:

In 2026, MedAdvisor's return on equity (ROE) was -57.41, a -373,986.77% increase from the 0.02 ROE in the previous year.

Access this data via the Eulerpool API

MedAdvisor Stock analysis

What does MedAdvisor do? Medadvisor Ltd is an Australian company that offers a digital platform for healthcare. Founded in 2012 by Robert Read, David Liu, and Josh Swinnerton, their aim was to develop a platform that simplifies medication management for patients, pharmacies, and doctors. Today, Medadvisor is a publicly traded company with a wide range of digital healthcare solutions. They offer various solutions to support patients in medication intake and management, such as a mobile application that allows patients to manage their medications, order prescriptions, and receive reminders. They also offer solutions for pharmacies, including an online ordering system and access to electronic patient history, as well as a platform for doctors to electronically issue prescriptions. One of their latest products is a mobile application that facilitates the handling of COVID-19, providing real-time virus spread tracking and symptom tracking tools. Medadvisor focuses on meeting customer needs and continuously improving the healthcare process. They recently partnered with Take2 Healthcare to expand their range of solutions and create the best offering of health solutions. Overall, Medadvisor plays an important role in the Australian healthcare system by helping their customers live happier and healthier lives through innovative technologies and services. MedAdvisor is one of the most popular companies on Eulerpool.

ROE Details

Decoding MedAdvisor's Return on Equity (ROE)

MedAdvisor's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing MedAdvisor's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

MedAdvisor's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in MedAdvisor’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about MedAdvisor stock

Return on Equity (ROE) of MedAdvisor amounted to 0.02 -57.41

Access this data via the Eulerpool API

Profitability — MedAdvisor

All Key Metrics — MedAdvisor